Author:
Amitay Yasmine,Shmeeda Hilary,Patil Yogita,Gorin Jenny,Tzemach Dina,Mak Lidia,Ohana Patricia,Gabizon Alberto
Funder
Israel Cancer Research Fund
Lipomedix Pharmaceuticals
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference33 articles.
1. Doll DC, Weiss RB, Issell BF. Mitomycin: ten years after approval for marketing. J Clin Oncol. 1985;3:276–86.
2. Sartorelli AC, Hodnick WF, Belcourt MF, Tomasz M, Haffty B, Fischer JJ, et al. Mitomycin C: a prototype bioreductive agent. Oncol Res. 1994;6:501–8.
3. Paz MM, Zhang X, Lu J, Holmgren A. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol. 2012;25:1502–11.
4. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995;2:575–9.
5. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3–8.
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献